Covered recipient · General Payments record
JOHN MICHAEL HUMENIUK
Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$2,895.44
65 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500.00 | 2 |
| Food and Beverage | $1,196.39 | 60 |
| Education | $184.99 | 2 |
| Travel and Lodging | $14.06 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $1,739.45 | 16 |
| Janssen Biotech, Inc. | $407.84 | 16 |
| UCB, Inc. | $148.26 | 5 |
| Amgen Inc. | $146.89 | 7 |
| Lilly USA, LLC | $114.20 | 6 |
| Janssen Scientific Affairs, LLC | $100.45 | 1 |
| PFIZER INC. | $92.01 | 5 |
| Novartis Pharmaceuticals Corporation | $57.76 | 4 |
| GENZYME CORPORATION | $56.75 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.66 | 1 |
| VYNE Pharmaceuticals Inc. | $15.17 | 1 |
Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN MICHAEL HUMENIUK
NPI 1639164528 · CMS profile ID 164457
Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology
GREER, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 65 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1639164528?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
65 matching records · $2,895.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 65.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $99.99 | 12/21/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213719 | CMS |
| Janssen Biotech, Inc. | $22.39 | 12/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213721 | CMS |
| Lilly USA, LLC | $16.85 | 12/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728492817 | CMS |
| Novartis Pharmaceuticals Corporation | $19.10 | 12/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725818693 | CMS |
| Amgen Inc. | $23.46 | 12/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741402043 | CMS |
| AbbVie Inc. | $16.42 | 12/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890657 | CMS |
| AbbVie Inc. | $5.15 | 12/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890653 | CMS |
| UCB, Inc. | $29.94 | 12/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746117563 | CMS |
| Lilly USA, LLC | $23.86 | 11/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728499573 | CMS |
| Janssen Biotech, Inc. | $13.42 | 11/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213735 | CMS |
| Janssen Biotech, Inc. | $9.28 | 11/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213725 | CMS |
| AbbVie Inc. | $19.28 | 11/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890649 | CMS |
| AbbVie Inc. | $15.64 | 11/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890645 | CMS |
| VYNE Pharmaceuticals Inc. | $15.17 | 11/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753205625 | CMS |
| PFIZER INC. | $22.70 | 11/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743513791 | CMS |
| Janssen Biotech, Inc. | $22.05 | 10/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213723 | CMS |
| Novartis Pharmaceuticals Corporation | $11.36 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725818689 | CMS |
| AbbVie Inc. | $29.35 | 10/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890643 | CMS |
| UCB, Inc. | $23.87 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746097513 | CMS |
| Amgen Inc. | $16.57 | 10/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741402041 | CMS |
| Janssen Biotech, Inc. | $14.50 | 09/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213733 | CMS |
| Lilly USA, LLC | $23.85 | 09/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728478585 | CMS |
| Janssen Biotech, Inc. | $24.57 | 09/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213715 | CMS |
| AbbVie Inc. | $20.23 | 09/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890639 | CMS |
| Janssen Biotech, Inc. | $14.69 | 08/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213717 | CMS |
| PFIZER INC. | $20.46 | 08/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743381363 | CMS |
| Amgen Inc. | $25.57 | 08/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741402039 | CMS |
| AbbVie Inc. | $1,200.00 | 08/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890635 | CMS |
| GENZYME CORPORATION | $18.33 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744039130 | CMS |
| Janssen Biotech, Inc. | $15.08 | 08/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213731 | CMS |
| AbbVie Inc. | $14.06 | 08/11/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890631 | CMS |
| AbbVie Inc. | $18.00 | 08/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890627 | CMS |
| UCB, Inc. | $30.13 | 08/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746087393 | CMS |
| AbbVie Inc. | $16.18 | 07/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890623 | CMS |
| Lilly USA, LLC | $12.72 | 07/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728499571 | CMS |
| Janssen Biotech, Inc. | $18.25 | 07/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213711 | CMS |
| AbbVie Inc. | $17.99 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890621 | CMS |
| PFIZER INC. | $18.94 | 06/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743248697 | CMS |
| AbbVie Inc. | $300.00 | 06/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890617 | CMS |
| UCB, Inc. | $33.29 | 06/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746063145 | CMS |
| AbbVie Inc. | $14.56 | 06/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890613 | CMS |
| Novartis Pharmaceuticals Corporation | $13.30 | 06/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725818683 | CMS |
| Janssen Biotech, Inc. | $29.76 | 06/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213709 | CMS |
| Amgen Inc. | $18.94 | 06/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741402035 | CMS |
| Amgen Inc. | $21.04 | 06/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741402037 | CMS |
| Lilly USA, LLC | $17.70 | 05/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728499569 | CMS |
| AbbVie Inc. | $18.10 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721890611 | CMS |
| GENZYME CORPORATION | $24.24 | 05/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744039017 | CMS |
| Janssen Biotech, Inc. | $7.54 | 05/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719213707 | CMS |
| PFIZER INC. | $18.04 | 05/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743181131 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,779.18 | 1 |
| PY2024 | Principal investigator | $1,014.39 | 1 |
| PY2021 | Principal investigator | $20,911.87 | 7 |
| PY2020 | Principal investigator | $203,548.79 | 150 |
| PY2019 | Principal investigator | $201,051.33 | 169 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
169 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514683 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514685 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514687 |
| Principal investigator 1 | Incyte Corporation | $997.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514689 |
| Principal investigator 1 | Incyte Corporation | $1,079.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514691 |
| Principal investigator 1 | Incyte Corporation | $991.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514693 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514695 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514707 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514709 |
| Principal investigator 1 | Incyte Corporation | $1,079.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514711 |
| Principal investigator 1 | Incyte Corporation | $1,079.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514713 |
| Principal investigator 1 | Incyte Corporation | $1,079.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514715 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514717 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514719 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514721 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514723 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514725 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514727 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514729 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514731 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514733 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514735 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514561 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514563 |
| Principal investigator 1 | Incyte Corporation | $997.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514565 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514567 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514569 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514571 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514573 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514615 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514617 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514619 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514621 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514623 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514625 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514627 |
| Principal investigator 1 | Incyte Corporation | $997.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514629 |
| Principal investigator 1 | Incyte Corporation | $997.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514631 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514633 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514635 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514637 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514639 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514641 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514643 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514645 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514647 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514649 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514651 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514653 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514655 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514657 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514659 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514661 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514663 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514665 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514667 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514669 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514697 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514699 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514701 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514703 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,193.13 | 11/13/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.63 | 11/06/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,963.31 | 11/06/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736767 |
| Principal investigator 1 | AbbVie, Inc. | $75.00 | 10/28/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583909 |
| Principal investigator 1 | AbbVie, Inc. | $1,616.00 | 10/21/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583911 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514549 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514551 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514553 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514555 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514557 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514559 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514575 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514577 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514579 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514581 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514583 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514585 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514587 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514589 |
| Principal investigator 1 | Incyte Corporation | $995.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514591 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514593 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514595 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514597 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514599 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514601 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514603 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514605 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514607 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514609 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514611 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/02/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514613 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.76 | 09/18/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736763 |
| Principal investigator 1 | UCB Biosciences Inc. | $187.53 | 09/13/2019 | Non-covered Recipient Entity RADIANT RESEARCH | A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 643247405 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514489 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514491 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514493 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514495 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514497 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514499 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514523 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514525 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514527 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514529 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514531 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514533 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514535 |
| Principal investigator 1 | Incyte Corporation | $1,076.00 | 09/03/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.63 | 08/28/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736757 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12.50 | 08/28/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 08/28/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $111.57 | 08/21/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736755 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514481 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514483 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514485 |
| Principal investigator 1 | Incyte Corporation | $46.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514487 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514511 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514513 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514515 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514517 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514519 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 08/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 07/31/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736749 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 07/31/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736751 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $106.25 | 07/31/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736753 |
| Principal investigator 1 | AbbVie, Inc. | $1,278.50 | 07/29/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583907 |
| Principal investigator 1 | AbbVie, Inc. | $75.00 | 07/26/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $889.33 | 07/24/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736747 |
| Principal investigator 1 | UCB SA | $187.53 | 07/18/2019 | Non-covered Recipient Entity RADIANT RESEARCH | A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 653520397 |
| Principal investigator 1 | Incyte Corporation | $1,169.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514501 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514503 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514505 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514507 |
| Principal investigator 1 | Incyte Corporation | $882.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514509 |
| Principal investigator 1 | Incyte Corporation | $1,502.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514539 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514541 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514543 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514545 |
| Principal investigator 1 | Incyte Corporation | $1,466.00 | 07/09/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC. GREER | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 666514547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $669.42 | 06/19/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 06/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736741 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.75 | 06/05/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736743 |
| Principal investigator 1 | AbbVie, Inc. | $1,616.00 | 05/29/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 05/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $118.75 | 05/22/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,863.65 | 05/15/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,099.18 | 04/17/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736733 |
| Principal investigator 1 | UCB SA | $373.43 | 04/15/2019 | Non-covered Recipient Entity RADIANT RESEARCH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 653520381 |
| Principal investigator 1 | AbbVie, Inc. | $2,709.50 | 03/28/2019 | Non-covered Recipient Entity Synexus Clinical Research US Inc | M15-997 | No dispute reported | 06/30/2026 | 647583913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,783.69 | 03/27/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736731 |
| Principal investigator 1 | Eli Lilly and Company | $111.45 | 03/26/2019 | Covered Recipient Teaching Hospital KALISPELL REGIONAL MEDICAL CENTER | A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654286019 |
| Principal investigator 1 | UCB SA | $7,438.40 | 03/14/2019 | Non-covered Recipient Entity RADIANT RESEARCH INC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 653521029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 03/13/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $118.75 | 03/13/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736729 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $48,099.15 | 03/12/2019 | Non-covered Recipient Entity Clinical Research Advantage, Incorporated | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | No dispute reported | 06/30/2026 | 639757749 |
| Principal investigator 1 | Eli Lilly and Company | $4,463.72 | 03/05/2019 | Non-covered Recipient Entity RADIANT RESEARCH INC | A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654292439 |
| Principal investigator 1 | PFIZER INC. | $1,482.00 | 02/28/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671619209 |
| Principal investigator 1 | PFIZER INC. | $590.00 | 02/26/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671619211 |
| Principal investigator 1 | PFIZER INC. | $225.00 | 02/25/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671621061 |
| Principal investigator 1 | PFIZER INC. | $61.62 | 02/25/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671621063 |
| Principal investigator 1 | PFIZER INC. | $42.38 | 02/25/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671621123 |
| Principal investigator 1 | PFIZER INC. | $49.95 | 02/25/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCHUS INC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671621125 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 02/22/2019 | Non-covered Recipient Entity Synexus | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 671641941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 02/04/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $118.75 | 02/04/2019 | Non-covered Recipient Entity SYNEXUS CLINICAL RESEARCH US INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736777 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.00 | 01/03/2019 | Non-covered Recipient Entity RADIANT RESEARCH INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.75 | 01/03/2019 | Non-covered Recipient Entity RADIANT RESEARCH INC | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 639736773 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,010.04 | 01/01/2019 | Non-covered Recipient Entity RADIANT RESEARCH | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ORAL ZPL389A 3 MG 10 MG 30 MG AND 50 MG CAPSULES ADMINISTERED FOR 16 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 640724577 |